However, very few diagnostic and prognostic markers have been reported with HPV-associated HNSCC subsets mainly limited to HPV, p16 and p53 (19), therefore, evaluating more biomarkers status, is highly required to predict the clinical outcome and survival of HPV-related HNSCC patients. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.